Mhc Class I Deficiency C6024714
A rare immune deficiency where cells lack surface markers needed for immune recognition, making patients highly vulnerable to viral infections. Bone marrow transplant may be curative.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Severe mucocutaneous herpesvirus infection
Granulomatous skin lesions
Generalized symptoms
(immunologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Recurrent upper respiratory tract infections
(immunologic)Chronic sinusitis
(immunologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Antiviral prophylaxis
Continuous antiviral medication prophylaxis prevents recurrent herpesvirus infections common in MHC class I deficiency. This reduces viral-related morbidity significantly in affected patients.
Drug therapy and clinical monitoring
Active treatment with regular monitoring by a healthcare provider is recommended.
Immunoglobulin replacement therapy
Intravenous or subcutaneous immunoglobulin provides passive humoral immunity to compensate for impaired T-cell and NK cell function. Regular infusions maintain protective antibody levels.
Additional treatment options
Infection surveillance and early intervention
Proactive monitoring for infections with low threshold for initiating antimicrobial therapy prevents serious complications. Regular imaging and laboratory screening for subclinical infections may be warranted.
monitoringInfection prevention practices
Education and implementation of rigorous hygiene measures, food safety practices, and avoidance of exposure to contagious illnesses significantly reduces infection risk in immunocompromised patients.
lifestyleHematopoietic stem cell transplantation
HSCT offers potential cure by replacing the defective immune system with healthy donor cells. This definitive treatment is considered when medical management is insufficient or disease burden is severe.
procedureWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Mhc Class I Deficiency C6024714?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Mhc Class I Deficiency C6024714. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy